Biomarin Pharmaceutical INC Form 4 insider transactions

Director Richard A. Meier acquired 6,650 shares of BioMarin Pharmaceutical Inc. common stock on May 20, 2025, through restricted stock units.

Cristin Hubbard, EVP and Chief Commercial Officer of BioMarin Pharmaceutical Inc., disposed of 2,155 shares of common stock on May 20, 2025, to satisfy tax withholding obligations.

Director Timothy P. Walbert reports acquisition of BioMarin Pharmaceutical Inc. shares through restricted stock units and disposal of indirect holdings.

Director Robert J. Hombach acquired 6,650 shares of BioMarin Pharmaceutical Inc. through restricted stock units on May 20, 2025.

Director Maykin Ho acquired 6,650 shares of BioMarin Pharmaceutical Inc. common stock on May 20, 2025, through restricted stock units.

Director Mark J Enyedy reports acquiring 6,650 shares of BioMarin Pharmaceutical Inc. common stock on May 20, 2025, through restricted stock units.

Director Dere Willard H. acquired 6,650 shares of BioMarin Pharmaceutical Inc. common stock on May 20, 2025, through restricted stock units.

Director Athena Countouriotis acquired 6,650 shares of BioMarin Pharmaceutical Inc. common stock through a restricted stock unit grant.

Director Barbara W. Bodem acquired 6,650 shares of BioMarin Pharmaceutical Inc. common stock on May 20, 2025, through restricted stock units.

Director Elizabeth Anderson reported the acquisition of 6,650 shares of BioMarin Pharmaceutical Inc. stock through a grant and the disposal of an unspecified amount of shares.

Erin Burkhart, GVP, Chief Accounting Officer of BioMarin Pharmaceutical Inc., reports the disposition of common stock on May 19 and 20, 2025, according to a Form 4 filing.

Cristin Hubbard, EVP and Chief Commercial Officer of BioMarin Pharmaceutical Inc., reports acquiring and disposing of company stock.

Erin Burkhart, GVP and Chief Accounting Officer of BioMarin Pharmaceutical Inc., sold 1,295 shares of common stock at $71.52 per share on March 19, 2025, under a pre-arranged 10b5-1 trading plan.

Erin Burkhart, GVP, Chief Accounting Officer of BioMarin Pharmaceutical Inc., reports acquisition and disposal of company stock and stock options.

Executive Vice President and Chief Legal Officer of BioMarin Pharmaceutical, George Eric Davis, reports acquisition and disposal of company stock and stock options.

EVP, Chief Commercial Officer of BioMarin Pharmaceutical, Cristin Hubbard, reports acquisition of stock options and restricted stock units (RSUs) along with the disposal of some shares.

Gregory R. Friberg, EVP and Chief R&D Officer of BioMarin Pharmaceutical Inc., reports acquisition of shares and stock options.

Charles Greg Guyer, EVP and Chief Technical Officer of BioMarin Pharmaceutical Inc., reports acquisition and disposal of company stock and stock options.

Brian Mueller, EVP and CFO of BioMarin Pharmaceutical Inc., reports the acquisition and disposal of company stock and stock options.

BioMarin's CEO, Alexander Hardy, reports the acquisition and disposal of company stock and stock options.

Charles Greg Guyer, EVP and Chief Technical Officer of BioMarin Pharmaceutical Inc., sold 7,034 shares of common stock on March 6, 2025.

EVP and Chief Technical Officer of BioMarin Pharmaceutical, Charles Greg Guyer, disposed of 4,287 shares of common stock on February 28, 2025, to satisfy tax withholding obligations.

EVP and CFO of BioMarin Pharmaceutical, Brian Mueller, reports acquisition of shares through vesting of Restricted Stock Units (RSUs) based on performance metrics.

Charles Greg Guyer, EVP and Chief Technical Officer of BioMarin Pharmaceutical Inc., acquired shares of common stock through the vesting of Restricted Stock Units (RSUs) based on performance metrics.

EVP and Chief Legal Officer of BioMarin Pharmaceutical, George Eric Davis, acquired shares of common stock through the vesting of Restricted Stock Units (RSUs) based on performance metrics.

Director Timothy P Walbert acquired 3,130 shares of BioMarin Pharmaceutical Inc. common stock on February 24, 2025, through restricted stock units.

Erin Burkhart, GVP, Chief Accounting Officer of BioMarin Pharmaceutical Inc., reports the sale of 1,344 shares of common stock on February 24, 2025, under a pre-arranged 10b5-1 trading plan.

BioMarin Pharmaceutical's CEO, Alexander Hardy, reported acquiring shares through the employee stock purchase plan and disposing of shares to cover tax obligations.

BioMarin's EVP, Chief Technical Officer, Charles Guyer, reported the acquisition of 55 shares and the sale of 5,278 shares of common stock.

Gregory Friberg, EVP and Chief R&D Officer at BioMarin Pharmaceutical Inc., reports the acquisition of restricted stock units and stock options.